Literature DB >> 33622323

Childhood-onset systemic lupus erythematosus with trisomy X and the increased risk for bone complications: a case report.

Susumu Yamazaki1,2, Yuko Akutsu3, Asami Shimbo3, Masaki Shimizu3, Yuko Segawa4, Masaaki Mori5.   

Abstract

BACKGROUND: Systemic lupus erythematosus is a multi-organ inflammatory autoimmune disease; immune complexes are part of the pathogenesis, but not entirely responsible. Trisomy X is the most common female chromosomal abnormality and the role of an additional X chromosome in the development of systemic lupus erythematosus is well recognized. However, the potential complications and optimal management of childhood lupus with trisomy X remain unclear. Herein, we describe a case of childhood-onset systemic lupus erythematosus associated with severe bone complications presumably secondary to trisomy X. CASE
PRESENTATION: A 16-year-old Japanese girl was diagnosed with childhood-onset systemic lupus erythematosus and trisomy X. A chromosomal abnormality (47, XXX) was incidentally identified on bone marrow examination initially done to determine the cause of pancytopenia. She had a persistent headache, fever for six days, diffuse hair loss, mucosal ulcers, butterfly eruptions, and palmar erythema. Furthermore, thrombocytopenia, anemia, and erythrocyte fragmentation were detected, suggesting secondary thrombotic microangiopathy. She was initially treated with intravenous methylprednisolone pulse therapy and prescribed monthly cyclophosphamide for severe disease activity, prednisolone, mycophenolate mofetil, and hydroxychloroquine as remission maintenance drugs. She developed generalized extremity pain that had been worsening throughout the disease. Extremity magnetic resonance imaging performed 12 months after the treatment onset revealed multifocal avascular necrosis, and dual-energy X-ray absorptiometry revealed further decreased bone mineral density. High plasma levels of factor VIII were detected by additional tests for coagulation functions, and we suspected the possibility that factor VIII might cause avascular necrosis due to thrombosis. Currently, she is being treated with prednisolone and MMF for SLE. However, her extremity pain has not been managed effectively even under the administration of non-steroidal anti-inflammatory drugs and pregabalin.
CONCLUSIONS: An additional X chromosome has been reported to be associated with factor VIII and osteoporosis. Additionally, elevated plasma levels of FVIII is the risk factors for thrombosis, which leads to the risk of avascular necrosis. Patients with systemic lupus erythematosus complicated by trisomy X might be at a higher risk of avascular necrosis and osteoporosis that can also manifest in childhood systemic lupus erythematosus.

Entities:  

Keywords:  Avascular necrosis; Corticosteroids; Osteoporosis; Systematic lupus erythematosus; Trisomy X

Year:  2021        PMID: 33622323      PMCID: PMC7903708          DOI: 10.1186/s12969-021-00507-3

Source DB:  PubMed          Journal:  Pediatr Rheumatol Online J        ISSN: 1546-0096            Impact factor:   3.054


  24 in total

Review 1.  Taxonomy for systemic lupus erythematosus with onset before adulthood.

Authors:  Clovis A Silva; Tadej Avcin; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-12       Impact factor: 4.794

2.  High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.

Authors:  P A Kyrle; E Minar; M Hirschl; C Bialonczyk; M Stain; B Schneider; A Weltermann; W Speiser; K Lechner; S Eichinger
Journal:  N Engl J Med       Date:  2000-08-17       Impact factor: 91.245

3.  Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis.

Authors:  J Justesen; K Stenderup; E N Ebbesen; L Mosekilde; T Steiniche; M Kassem
Journal:  Biogerontology       Date:  2001       Impact factor: 4.277

4.  Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment.

Authors:  K Oinuma; Y Harada; Y Nawata; K Takabayashi; I Abe; K Kamikawa; H Moriya
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

Review 5.  A review of trisomy X (47,XXX).

Authors:  Nicole R Tartaglia; Susan Howell; Ashley Sutherland; Rebecca Wilson; Lennie Wilson
Journal:  Orphanet J Rare Dis       Date:  2010-05-11       Impact factor: 4.123

6.  Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study.

Authors:  Angelo Ravelli; Carolina Duarte-Salazar; Silvia Buratti; Andreas Reiff; Bram Bernstein; Maria Rocio Maldonado-Velazquez; Rosalia Beristain-Manterola; Nobuaki Maeno; Syuji Takei; Valeria Gerloni; Charles H Spencer; Polyxeni Pratsidou-Gertsi; Nicolino Ruperto; Angela Pistorio; Alberto Martini
Journal:  Arthritis Rheum       Date:  2003-08-15

7.  Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  M G Conlan; A R Folsom; A Finch; C E Davis; P Sorlie; G Marcucci; K K Wu
Journal:  Thromb Haemost       Date:  1993-09-01       Impact factor: 5.249

Review 8.  Genetic regulation of plasma von Willebrand factor levels in health and disease.

Authors:  L L Swystun; D Lillicrap
Journal:  J Thromb Haemost       Date:  2018-10-30       Impact factor: 5.824

9.  Quantitative Influence of ABO Blood Groups on Factor VIII and Its Ratio to von Willebrand Factor, Novel Observations from an ARIC Study of 11,673 Subjects.

Authors:  Jaewoo Song; Fengju Chen; Marco Campos; Doug Bolgiano; Katie Houck; Lloyd E Chambless; Kenneth K Wu; Aaron R Folsom; David Couper; Eric Boerwinkle; Jing-fei Dong
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

View more
  1 in total

Review 1.  Systemic lupus erythematosus with trisomy X: a case report and review of the literature.

Authors:  Fang Luo; Qiao Ye; Jie Shen
Journal:  J Med Case Rep       Date:  2022-07-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.